2003: Human Genome Project Completed (2003)

The formal completion of the Human Genome Project (HGP) in April 2003—50 years to the month after
Watson and Crick published the double helix structure—delivered a reference sequence covering
99 % of the human euchromatic genome to an accuracy of 99.999 %, at a total cost of approximately
$3 billion over 13 years. The international consortium, coordinated by the National Human Genome
Research Institute and the Wellcome Trust, sequenced DNA from a small number of anonymous donors
using Sanger-based capillary electrophoresis across 20 sequencing centres in six countries. A
competing effort by Celera Genomics, using whole-genome shotgun sequencing led by J. Craig Venter,
published a draft sequence simultaneously in February 2001, accelerating the timeline.

The reference genome revealed approximately 20,500 protein-coding genes—far fewer than the 100,000
estimate prevalent in the 1990s—and demonstrated that coding sequences account for only about
1.5 % of the genome, with the remainder comprising regulatory elements, non-coding RNAs, repetitive
elements, and sequences of uncertain function. The extensive non-coding landscape proved as
biologically consequential as coding regions, harbouring millions of single-nucleotide polymorphisms
(SNPs) and structural variants associated with disease susceptibility.

The HGP's impact on drug discovery has been profound and cumulative. Genome-wide association
studies (GWAS) enabled in the post-HGP era identified thousands of loci associated with common
diseases, providing hypothesis-generating targets for drug programmes. Target validation was
transformed: Mendelian randomisation and human genetic data from biobanks such as UK Biobank
now allow researchers to assess whether a target's biology, as observed in human populations,
supports the intended therapeutic mechanism before committing to drug development—reducing late-
stage attrition.